Access Bio, COVID-19 (Diagnosis/Treatment/Vaccine Development, etc.) Theme Rises 11.45%

On the 19th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.58% compared to the previous day, showing strength, while Access Bio, a related stock drawing attention, surged by 11.45% compared to the previous day. Access Bio is known as a specialized manufacturer of in vitro diagnostic products such as malaria diagnostic kits.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Access Bio’s quant financial score was 7.73 points, ranking 40th in the quant financial ranking within the COVID-19 (diagnosis/treatment/vaccine development, etc.) related theme. This can be interpreted as Access Bio having relatively low investment attractiveness from a financial perspective. On the other hand, United Pharm ranked first in the quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the robo algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.